TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04805242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose Prolotherapy Injection
Description: Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline Injection
Description: Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions.
Study: NCT04993183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-day PLUS Convention
Description: Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
Study: NCT04889326

Intervention type: OTHER
Intervention: Retrospective data and biological samples
Description: Analysis of data and biological samples collected during hospitalization:
Study: NCT04816643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 10mcg
Description: BNT162b2 Low/Mid-Dose (10mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 10mcg
Description: BNT162b2 Low/Mid-Dose (10mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 10mcg
Description: BNT162b2 Low/Mid-Dose (10mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 10mcg
Description: BNT162b2 Low/Mid-Dose (10mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 20mcg
Description: BNT162b2 Mid-Dose (20mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 20mcg
Description: BNT162b2 Mid-Dose (20mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 20mcg
Description: BNT162b2 Mid-Dose (20mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 30mcg
Description: BNT162b2 High-Dose (30mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 30mcg
Description: BNT162b2 High-Dose (30mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 30mcg
Description: BNT162b2 High-Dose (30mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 30mcg
Description: BNT162b2 High-Dose (30mcg) level

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 3mcg
Description: BNT162b2 Low-Dose (3mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 3mcg
Description: BNT162b2 Low-Dose (3mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 3mcg
Description: BNT162b2 Low-Dose (3mcg) level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BNT162b2 3mcg
Description: BNT162b2 Low-Dose (3mcg) level
Study: NCT01117974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liposuction of the neck
Description: Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
Study: NCT05520008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game-based exercise
Description: Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
Study: NCT05400616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiome Transplant
Description: A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline.
Study: NCT05372120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-192
Description: ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
Study: NCT05695716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSI pVAD System
Description: The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
Study: NCT06583330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin (dalteparin)
Description: All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (dalteparin)
Description: All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.
Study: NCT06583902

Intervention type: DRUG
Intervention: Intravenous iron
Description: Patients with an absolute deficiency (ferritin ≤100 μg/L) or functional deficiency (ferritin ≤ 300 μg/L with transferrin saturation ≤20%) receive iron supplementation, through a single administration of an iron preparation for intravenous use administered according to the doses present in the technical data sheet.

Intervention type: OTHER
Intervention: Retrospective case-control analysis
Description: the only routine clinical data collection (Hb, iron status, direct and indirect Coombs test, IL6, erythropoietin dosage, number of units of blood components possibly transfused)
Study: NCT06584526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the experimental groups).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy and Aerobic Exercise
Description: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a cycle ergometer.
Study: NCT05481671

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be asked to respond to the Demographic Information Sheet, Tampa Scale for Kinesiophobia, Numeric Rating Scale, Pain Catastrophizing Scale, Hospital Anxiety and Depression Scale, Resilience Scale , Pain Self-efficacy Questionnaires and Functional Exercise Compliance Scale for Orthopaedic Patients.
Study: NCT03586089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital Sodium
Description: Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo
Description: Single dose of inactive placebo prepared in 250 ml D5W).
Study: NCT05590364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profhilo® Body
Description: Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
Study: NCT06194968

Intervention type: DRUG
Intervention: Urokinase
Description: administered intravenously

Intervention type: DRUG
Intervention: Alteplase
Description: administered intravenously
Study: NCT06584526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy and Strength Exercise
Description: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes strength exercise programme.
Study: NCT05602701

Intervention type: OTHER
Intervention: Preoperative assessment
Description: Preoperative assessment of physical fitness
Study: NCT05355948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO Patch PLUS for 1 day
Description: Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
Study: NCT04722250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems
Description: TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems
Description: TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
Study: NCT05193955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: Laughter yoga is one of the methods that is among the complementary therapy and supportive care practices in the world and is used increasingly. Laughter yoga is a non-invasive and non-pharmacological method that combines unconditional laughter with yoga breathing techniques. In laughter yoga, one can laugh without being humorous, joking, or funny. Laughter is simulated by starting out as a physical exercise and making eye contact with other members of the group and playing games with them. The body cannot distinguish between real and unreal laughter and laughter begins.
Study: NCT05338827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polyvinyl Chloride Tube group
Description: The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wire-Reinforced Tube group
Description: The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
Study: NCT06269562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus posterior superior intercostal plane block and clavipectoral plane block
Description: The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
Study: NCT05896709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MK-RS
Description: The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
Study: NCT05799976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message nudge
Description: The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
Study: NCT05355948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO Patch PLUS for More than 8-days
Description: Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days \~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
Study: NCT05962892

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05293691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body, Breath & Mind
Description: The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Body, Breath & Mind
Description: The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moodgym
Description: Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
Study: NCT04783389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection.
Study: NCT06184100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Self-Management Program (SMP)
Description: Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
Study: NCT05847634

Intervention type: DEVICE
Intervention: Masimo O3 NIRS cerebral oximetry and SedLine processed EEG
Description: Non-invasive neuromonitoring device for observational study
Study: NCT06184100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: No intervention. Participant only receives standard of care.
Study: NCT06273072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride extended-release tablets
Description: titrated to 2000 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Visually identical placebo Metformin hydrochloride extended-release tablets
Description: placebo
Study: NCT06526663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vignette exposure
Description: Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes.
Study: NCT04859465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane combined with liposomal doxorubicin
Description: Patients with advanced or unresectable angiogenic sarcoma who met the criteria of treatment failure received abraxane combined with liposomal doxorubicin regimen. Administration regimen: abraxane 220 mg / m2 D1 plus liposomal doxorubicin 35 mg / m2 D1, IV drip, 3 weeks as a cycle, until the disease progression or intolerable toxicity. Up to 8 cycles.
Study: NCT06014671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Intervention Group were took interpersonal psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Intervention Group were took interpersonal psychotherapy
Study: NCT06584955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted Blanket
Description: Participants will be given a weighted blanket
Study: NCT06313944

Intervention type: DIAGNOSTIC_TEST
Intervention: Registry
Description: Clinical data collection of patients scheduled for on-label treatment
Study: NCT04759378

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Upper endoscopy, esophageal manometry, 24-hour pH monitoring
Description: upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
Study: NCT05644067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SumayaVac-1(SUM-101)
Description: One immunization every 4 weeks for 3 months (total 3 immunizations)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Verorab
Description: One immunization every 4 weeks for 3 months (total 3 immunizations)
Study: NCT06527833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Packing of perianal abscess cavity after drainage
Description: * All patients will undergo incision and drainage under general anaesthesia.~* In Group (A \[Non-Packing group\]), The surgery will be performed by making a cruciate incision over the abscess and incision widened using forceps to allow complete drainage of the cavity containing, without any catheter drainage and packing avoided. The lesion will be left open to heal by secondary intention. The patient was advised to have a sitz bath and apply a dressing over the cavity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Packing of perianal abscess cavity after drainage
Description: an elliptical incision will be made, and the abscess will be fully drained then packing the cavity will be done with sterile gauze with a change of dressing every 24 hours until it is completely healed.
Study: NCT05100576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine system users
Description: Telemonitoring by medical devices connected to a software system with a router.
Study: NCT06429293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy
Description: The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician
Study: NCT04942678

Intervention type: BEHAVIORAL
Intervention: 10-minute visit with therapy dog and child life specialist handler
Description: A visit from a therapy dog and child life specialist will occur which will last for approximately 10 minutes. Parents and patients will be asked to sanitize their hand prior to the visit. The child life specialist will be instructed to have ad lib conversation with the family. The dog will remain on a leash during the visit. The patient will be free to pet the therapy dog if they wish.

Intervention type: BEHAVIORAL
Intervention: 10-minute visit with therapy dog and child life specialist handler
Description: A visit from a therapy dog and child life specialist will occur which will last for approximately 10 minutes. Parents and patients will be asked to sanitize their hand prior to the visit. The child life specialist will be instructed to have ad lib conversation with the family. The dog will remain on a leash during the visit. The patient will be free to pet the therapy dog if they wish.